BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Core Viewpoint - BioLineRx Ltd. is set to release its unaudited financial results for Q2 2025 on August 14, 2025, before U.S. markets open, indicating ongoing developments in its biopharmaceutical pipeline [1]. Company Overview - BioLineRx Ltd. is a biopharmaceutical company focused on developing therapies for oncology and rare diseases, with its first approved product being APHEXDA® (motixafortide) for stem cell mobilization in multiple myeloma [4]. - The company is leveraging its expertise in development, regulatory affairs, manufacturing, and commercialization to advance its innovative pipeline [4]. Conference Call Details - A conference call will be held at 8:30 a.m. EDT featuring remarks from the CEO, Philip Serlin [2]. - Access to the conference call can be obtained via specific dial-in numbers for U.S. and international participants, with a live webcast available on the company's website [3].